HSPD1 and type 1 diabetes mellitus: HSP60-based immuno-regulation is being exploited clinically for the treatment of autoimmune disorders; the administration of a peptide from human HSP60 has been reported to halt β-cell destruction in newly diagnosed T1DM patients [12], [13] and to halt experimental Sjögren's syndrome [14].